Literature DB >> 27896993

FREQUENT SUBGRAPH MINING OF PERSONALIZED SIGNALING PATHWAY NETWORKS GROUPS PATIENTS WITH FREQUENTLY DYSREGULATED DISEASE PATHWAYS AND PREDICTS PROGNOSIS.

Arda Durmaz1, Tim A D Henderson, Douglas Brubaker, Gurkan Bebek.   

Abstract

MOTIVATION: Large scale genomics studies have generated comprehensive molecular characterization of numerous cancer types. Subtypes for many tumor types have been established; however, these classifications are based on molecular characteristics of a small gene sets with limited power to detect dysregulation at the patient level. We hypothesize that frequent graph mining of pathways to gather pathways functionally relevant to tumors can characterize tumor types and provide opportunities for personalized therapies.
RESULTS: In this study we present an integrative omics approach to group patients based on their altered pathway characteristics and show prognostic differences within breast cancer (p < 9:57E - 10) and glioblastoma multiforme (p < 0:05) patients. We were able validate this approach in secondary RNA-Seq datasets with p < 0:05 and p < 0:01 respectively. We also performed pathway enrichment analysis to further investigate the biological relevance of dysregulated pathways. We compared our approach with network-based classifier algorithms and showed that our unsupervised approach generates more robust and biologically relevant clustering whereas previous approaches failed to report specific functions for similar patient groups or classify patients into prognostic groups.
CONCLUSIONS: These results could serve as a means to improve prognosis for future cancer patients, and to provide opportunities for improved treatment options and personalized interventions. The proposed novel graph mining approach is able to integrate PPI networks with gene expression in a biologically sound approach and cluster patients in to clinically distinct groups. We have utilized breast cancer and glioblastoma multiforme datasets from microarray and RNA-Seq platforms and identified disease mechanisms differentiating samples. SUPPLEMENTARY INFORMATION: Supplementary methods, figures, tables and code are available at https://github.com/bebeklab/dysprog.

Entities:  

Mesh:

Year:  2017        PMID: 27896993      PMCID: PMC6029858          DOI: 10.1142/9789813207813_0038

Source DB:  PubMed          Journal:  Pac Symp Biocomput        ISSN: 2335-6928


  44 in total

1.  Learning the parts of objects by non-negative matrix factorization.

Authors:  D D Lee; H S Seung
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

2.  Gene expression profiling of gliomas strongly predicts survival.

Authors:  William A Freije; F Edmundo Castro-Vargas; Zixing Fang; Steve Horvath; Timothy Cloughesy; Linda M Liau; Paul S Mischel; Stanley F Nelson
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

3.  Metagenes and molecular pattern discovery using matrix factorization.

Authors:  Jean-Philippe Brunet; Pablo Tamayo; Todd R Golub; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

Review 4.  Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis.

Authors:  Lawrence B Gardner
Journal:  Mol Cancer Res       Date:  2010-02-23       Impact factor: 5.852

5.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.

Authors:  Janice M Nigro; Anjan Misra; Li Zhang; Ivan Smirnov; Howard Colman; Chandi Griffin; Natalie Ozburn; Mingang Chen; Edward Pan; Dimpy Koul; W K Alfred Yung; Burt G Feuerstein; Kenneth D Aldape
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  The Reactome pathway knowledgebase.

Authors:  David Croft; Antonio Fabregat Mundo; Robin Haw; Marija Milacic; Joel Weiser; Guanming Wu; Michael Caudy; Phani Garapati; Marc Gillespie; Maulik R Kamdar; Bijay Jassal; Steven Jupe; Lisa Matthews; Bruce May; Stanislav Palatnik; Karen Rothfels; Veronica Shamovsky; Heeyeon Song; Mark Williams; Ewan Birney; Henning Hermjakob; Lincoln Stein; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2013-11-15       Impact factor: 16.971

10.  Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Authors:  Saverio Tardito; Anaïs Oudin; Shafiq U Ahmed; Fred Fack; Olivier Keunen; Liang Zheng; Hrvoje Miletic; Per Øystein Sakariassen; Adam Weinstock; Allon Wagner; Susan L Lindsay; Andreas K Hock; Susan C Barnett; Eytan Ruppin; Svein Harald Mørkve; Morten Lund-Johansen; Anthony J Chalmers; Rolf Bjerkvig; Simone P Niclou; Eyal Gottlieb
Journal:  Nat Cell Biol       Date:  2015-11-23       Impact factor: 28.824

View more
  1 in total

1.  Genetic Association between Amyotrophic Lateral Sclerosis and Cancer.

Authors:  Y-H Taguchi; Hsiuying Wang
Journal:  Genes (Basel)       Date:  2017-09-27       Impact factor: 4.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.